IL-31-Receptor‑α Antagonist Nemolizumab in Treatment‑Refractory Brachioradial Pruritus: A Case Report - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Nemolizumab, an IL-31 Receptor-α Antagonist, for Refractory Brachioradial Pruritus: A Case Report

  • By

  • Manuel P. Pereira

  • Eva M. Grekowitz

  • Martin Metz

  • November 20, 2026

Share

  • 1

    A 65-year-old woman had more than 4 years of bilateral arm pruritus, burning, and pain consistent with brachioradial pruritus.

  • 2

    Symptoms persisted despite topical therapies, gabapentin, pregabalin, and naltrexone, with substantial impairment of sleep and quality of life.

  • 3

    Nemolizumab was initiated with a 60-mg loading dose followed by 30 mg every 4 weeks, while pregabalin and naltrexone continued.

  • 4

    Within 10 days, the worst itch numerical rating score fell from 7–9 of 10 to 3 of 10 and generally remained at 0–1 of 10 during 3 months of follow-up.

  • 5

    Quality-of-life scores improved markedly, but the single case, concomitant treatment, and brief follow-up limit conclusions; further studies are needed.

Original Source(s)

Related Content